0001661059 false 0001661059 2025-04-10 2025-04-10

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 10, 2025

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) |  | 001-38905 (Commission File Number) |  | 47-5231247 (IRS Employer Identification No.)

​ ​ |  |
9000 Virginia Manor Road, Suite 200 Beltsville, Maryland |  | 20705
(Address of principal |  | (Zip Code)
executive offices) |  |

Registrant's telephone number, including area code: (240) 399-4900

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.001 par value per share | NXTC | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

​

On April 10, 2025, NextCure, Inc. (the “Company”) updated its corporate presentation to reflect updates on its ongoing clinical trial of LNCB74. Beginning on April 10, 2025, the Company will be engaging with members of the investment community, which may reference these presentation materials. The Company is furnishing a copy of such presentation materials, which is attached hereto as Exhibit 99.1.

​

The information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

​

​

​

​

Item 9.01 Financial Statements and Exhibits

​

(d) Exhibits.

​

​ | ​ |
Exhibit No. | ​ | Description
99.1 | ​ | NextCure, Inc. Presentation dated April 10, 2025
104 | ​ | Cover Page Interactive Data File (embedded within the inline XBRL document)

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November |  |
Dated: April 10, 2025 | NEXTCURE, INC. ​
| By: | /s/ Steven P. Cobourn
| Name: | Steven P. Cobourn
| Title: | Chief Financial Officer

​

​

​

​

​